Where are they now? Catching up with past Fierce 15 honorees

The Top Line

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 

These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.

Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 

In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.

To learn more about the topics in this episode: 

  • Introducing Fierce Biotech's 2024 Fierce 15

  • Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline

  • Synthekine hopes new IL-2 will be the high-alpha in a beta class 

See omnystudio.com/listener for privacy information.

若要收聽兒少不宜的單集,請登入帳號。

隨時掌握此節目最新消息

登入或註冊後,即可追蹤節目、儲存單集和掌握最新資訊。

選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大